Literature DB >> 32647136

Modeling oncolytic virus dynamics in the tumor microenvironment using zebrafish.

David Mealiea1,2,3, Emilie Boudreau4, Naomi De Silva4, Lili Okamoto4,5, Tiffany Ho4, Jason E Fish4,6, J Andrea McCart7,4,5.   

Abstract

We have adapted a zebrafish (Danio rerio) tumor xenograft model for use in the study of oncolytic virotherapy. Following implantation of mammalian cancer cells into the perivitelline space of developing zebrafish embryos, both local and intravenous oncolytic virus treatments produce a tumor-specific infection with measurable antitumor effects. Tumor cells are injected at 48 h post fertilization, with oncolytic virus treatment then being administered 24 h later to allow for an initial period of tumor development and angiogenesis. Confocal fluorescent imaging is used to quantify dynamics within the tumor environment. The natural translucency of zebrafish at the embryo stage, coupled with the availability of strains with fluorescent immune and endothelial cell reporter lines, gives the model broad potential to allow for real time, in vivo investigation of important events within tumors throughout the course of virotherapy. Zebrafish xenografts offer a system with biologic fidelity to processes in human cancer development that influence oncolytic virus efficacy, and to our knowledge this is the first demonstration of the model's use in the context of virotherapy. Compared with other models, our protocol offers a powerful, inexpensive approach to evaluating novel oncolytic viruses and oncolytic virus-based combination therapies, with potential application to investigating the impacts of virotherapy on immune response, tumor vasculature, and metastatic disease.
© 2020. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Mesh:

Year:  2020        PMID: 32647136     DOI: 10.1038/s41417-020-0194-7

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  72 in total

1.  The Role of Neutrophils in Measles Virus-mediated Oncolysis Differs Between B-cell Malignancies and Is Not Always Enhanced by GCSF.

Authors:  Aditi Dey; Yu Zhang; Anna Z Castleton; Katharine Bailey; Brendan Beaton; Bella Patel; Adele K Fielding
Journal:  Mol Ther       Date:  2015-08-17       Impact factor: 11.454

2.  A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

Authors:  J Fueyo; C Gomez-Manzano; R Alemany; P S Lee; T J McDonnell; P Mitlianga; Y X Shi; V A Levin; W K Yung; A P Kyritsis
Journal:  Oncogene       Date:  2000-01-06       Impact factor: 9.867

3.  ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents.

Authors:  C Heise; A Sampson-Johannes; A Williams; F McCormick; D D Von Hoff; D H Kirn
Journal:  Nat Med       Date:  1997-06       Impact factor: 53.440

4.  Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.

Authors:  Dipongkor Saha; Robert L Martuza; Samuel D Rabkin
Journal:  Cancer Cell       Date:  2017-08-14       Impact factor: 31.743

Review 5.  Zebrafish patient avatars in cancer biology and precision cancer therapy.

Authors:  Maurizio Fazio; Julien Ablain; Yan Chuan; David M Langenau; Leonard I Zon
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

6.  Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

Authors:  Robert H I Andtbacka; Howard L Kaufman; Frances Collichio; Thomas Amatruda; Neil Senzer; Jason Chesney; Keith A Delman; Lynn E Spitler; Igor Puzanov; Sanjiv S Agarwala; Mohammed Milhem; Lee Cranmer; Brendan Curti; Karl Lewis; Merrick Ross; Troy Guthrie; Gerald P Linette; Gregory A Daniels; Kevin Harrington; Mark R Middleton; Wilson H Miller; Jonathan S Zager; Yining Ye; Bin Yao; Ai Li; Susan Doleman; Ari VanderWalde; Jennifer Gansert; Robert S Coffin
Journal:  J Clin Oncol       Date:  2015-05-26       Impact factor: 44.544

7.  Tumor vascularization is critical for oncolytic vaccinia virus treatment of peritoneal carcinomatosis.

Authors:  Kathryn Ottolino-Perry; Nan Tang; Renee Head; Calvin Ng; Rozanne Arulanandam; Fernando A Angarita; Sergio A Acuna; Yonghong Chen; John Bell; Ralph S Dacosta; J Andrea McCart
Journal:  Int J Cancer       Date:  2013-08-29       Impact factor: 7.396

8.  Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.

Authors:  Caroline J Breitbach; Rozanne Arulanandam; Naomi De Silva; Steve H Thorne; Richard Patt; Manijeh Daneshmand; Anne Moon; Carolina Ilkow; James Burke; Tae-Ho Hwang; Jeong Heo; Mong Cho; Hannah Chen; Fernando A Angarita; Christina Addison; J Andrea McCart; John C Bell; David H Kirn
Journal:  Cancer Res       Date:  2013-02-07       Impact factor: 12.701

9.  Development of a novel zebrafish xenograft model in ache mutants using liver cancer cell lines.

Authors:  M Ender Avci; Ayse Gokce Keskus; Seniye Targen; M Efe Isilak; Mehmet Ozturk; Rengul Cetin Atalay; Michelle M Adams; Ozlen Konu
Journal:  Sci Rep       Date:  2018-01-25       Impact factor: 4.379

View more
  1 in total

1.  Cancer gene therapy 2020: highlights from a challenging year.

Authors:  Georgios Giamas; Teresa Gagliano
Journal:  Cancer Gene Ther       Date:  2021-05-07       Impact factor: 5.854

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.